Market Announcement



12 April 2024

Amplia Therapeutics Limited (ASX: ATX) – Trading Halt

Description

The securities of Amplia Therapeutics Limited ('ATX') will be placed in trading halt at the request of ATX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 16 April 2024 or when the announcement is released to the market.

Issued by

ASX Compliance



12 April 2024

REQUEST FOR TRADING HALT

Amplia Therapeutics Limited requests a Trading Halt in respect of the Company's securities:

- A Trading Halt is requested to allow Amplia to undertake an entitlement offer process.
- The Company expects that the Trading Halt will be required for up to 2 days with normal trading to resume on Tuesday 16 April 2024.
- The Company will lodge an announcement for release to the market regarding the capital raising to end the trading halt.
- The Company is not aware of any reason why a Trading Halt should not be granted or any other information necessary to inform the market about the Trading Halt.

This ASX announcement was approved and authorised for release by the Chief Executive Officer.

- End -

Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit <u>www.ampliatx.com</u> and follow Amplia on <u>Twitter</u> (@ampliatx), <u>Threads</u> (@ampliatx) and <u>LinkedIn</u>.